New User? Click here to register

Imaging assessment of metastatic Breast Cancer.

Text generated by AI based on an exclusive interview, revised and reviewed by

Dr Jean-Philippe MINART, Cannes, France

October 20, 2023

Dalila AHNOU
Radiology

What are the options in HER2 postive breast cancer treatments are we moving to t-DXd in first line?
Hassan GHAZAL
oncologist, Dubai
HER2-Targeted Therapies: Beyond Trastuzumab
Hassan GHAZAL
At what stage do you integrate liquid biopsy into breast cancer management? How early?
Simon NAYLER
pathologist, Johanesburgh, South Africa
What strategy to use to manage side effects in practice?
Georgia DEMETRIOU
oncologist, Johannesburg, SA
What is the benefit of simultaneous integrated boost against sequential boost?
Yazid BELKACEMI
radiotherapist, Créteil, France